DK1496944T3 - Forbedrede rAAV-ekspressionssystemer til genetisk modificering af specifikke sapsid-proteiner - Google Patents
Forbedrede rAAV-ekspressionssystemer til genetisk modificering af specifikke sapsid-proteinerInfo
- Publication number
- DK1496944T3 DK1496944T3 DK03786493T DK03786493T DK1496944T3 DK 1496944 T3 DK1496944 T3 DK 1496944T3 DK 03786493 T DK03786493 T DK 03786493T DK 03786493 T DK03786493 T DK 03786493T DK 1496944 T3 DK1496944 T3 DK 1496944T3
- Authority
- DK
- Denmark
- Prior art keywords
- vectors
- expression systems
- proteins
- sapsid
- raav
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/858—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from apolipopeptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37731502P | 2002-05-01 | 2002-05-01 | |
PCT/US2003/013583 WO2004027019A2 (fr) | 2002-05-01 | 2003-05-01 | Systemes d'expression raav ameliores destines a une modification genetique de proteines de capside specifiques |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1496944T3 true DK1496944T3 (da) | 2008-12-01 |
Family
ID=32030574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03786493T DK1496944T3 (da) | 2002-05-01 | 2003-05-01 | Forbedrede rAAV-ekspressionssystemer til genetisk modificering af specifikke sapsid-proteiner |
Country Status (11)
Country | Link |
---|---|
US (2) | US8802080B2 (fr) |
EP (1) | EP1496944B1 (fr) |
AT (1) | ATE405295T1 (fr) |
AU (1) | AU2003295312B2 (fr) |
CA (1) | CA2483624A1 (fr) |
DE (1) | DE60323078D1 (fr) |
DK (1) | DK1496944T3 (fr) |
HK (1) | HK1071518A1 (fr) |
NZ (2) | NZ561656A (fr) |
SI (1) | SI1496944T1 (fr) |
WO (1) | WO2004027019A2 (fr) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060093589A1 (en) * | 2004-02-19 | 2006-05-04 | Warrington Kenneth H | Vp2-modified raav vector compositions and uses therefor |
NZ561656A (en) | 2002-05-01 | 2009-03-31 | Univ Florida | Improved rAAV expression systems for genetic modification of specific capsid proteins |
WO2004099423A1 (fr) * | 2003-05-01 | 2004-11-18 | University Of Florida Research Foundation, Inc. | Vecteurs raav modifies par vp2 et leurs utilisations |
US20040179028A1 (en) * | 2003-03-12 | 2004-09-16 | Fuji Photo Film Co., Ltd. | Pixel defect correcting method, color mura correcting method and image display device |
EP1486567A1 (fr) * | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Vecteur derivé d'un virus associé aux adenovirus pour la thérapie génique |
ES2329636B2 (es) | 2006-02-17 | 2010-07-26 | Universitat De Valencia, Estudi General (Participa Con El 70%) | Uso del factor pedf para inducir la auto-renovacion de celulas madre. |
US9611302B2 (en) | 2007-04-09 | 2017-04-04 | University Of Florida Research Foundation, Inc. | High-transduction-efficiency RAAV vectors, compositions, and methods of use |
US9725485B2 (en) | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
EP3492596A1 (fr) | 2007-04-09 | 2019-06-05 | University of Florida Research Foundation, Inc. | Compositions de vecteur raav comprenant des protéines de capside à tyrosine modifié et procédés d'utilisation |
JP2011512417A (ja) * | 2008-02-20 | 2011-04-21 | ジェンザイム・コーポレーション | 血管形成の阻害 |
EP2910637A1 (fr) | 2008-05-20 | 2015-08-26 | University of Florida Research Foundation, Inc. | Vecteurs pour la délivrance de protéines photosensibles et procédés d'utilisation |
US8889641B2 (en) | 2009-02-11 | 2014-11-18 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
PT2403867T (pt) | 2009-03-04 | 2019-08-29 | Deutsches Krebsforsch | Proteína de ativação de montagem (aap) e a sua utilização para o fabrico de partículas de parvovírus essenciais consistindo de vp3 |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
AU2011336470B8 (en) | 2010-12-01 | 2017-09-14 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
EP2500434A1 (fr) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique |
JP6348064B2 (ja) * | 2011-11-22 | 2018-06-27 | ザ チルドレンズ ホスピタル オブ フィラデルフィア | 効率の高いトランスジーン送達のためのウイルスベクター |
US10294281B2 (en) | 2012-05-15 | 2019-05-21 | University Of Florida Research Foundation, Incorporated | High-transduction-efficiency rAAV vectors, compositions, and methods of use |
PT3024498T (pt) | 2013-07-22 | 2020-03-06 | Childrens Hospital Philadelphia | Variante aav e composições, métodos e usos para transferência genética em células, órgãos e tecidos |
CN104592364B (zh) * | 2013-10-30 | 2018-05-01 | 北京大学 | 定点突变和定点修饰的腺相关病毒、其制备方法及应用 |
WO2015085300A1 (fr) * | 2013-12-06 | 2015-06-11 | Johnson Matthey Public Limited Company | Catalyseur de démarrage à froid et son utilisation dans des systèmes d'échappement |
GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
CA2941640A1 (fr) | 2014-03-04 | 2015-09-11 | University Of Florida Research Foundation, Inc. | Vecteurs raav ameliores et procedes pour la transduction de photorecepteurs et cellules epr |
EP3137497B1 (fr) | 2014-05-02 | 2021-04-07 | Genzyme Corporation | Vecteurs aav pour thérapie génique de la rétine et du snc |
WO2015191508A1 (fr) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Capsides chimériques |
DK3198018T3 (da) * | 2014-09-24 | 2021-03-01 | Hope City | Vektorvarianter af adenoassocieret virus til højeffektiv genomredigering og fremgangsmåder dertil |
JP6401871B2 (ja) | 2014-11-05 | 2018-10-10 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | パーキンソン病の治療のためのaadcポリヌクレオチド |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
SG11201703419UA (en) | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
EP3218484A4 (fr) | 2014-11-14 | 2018-05-30 | Voyager Therapeutics, Inc. | Compositions et méthodes de traitement de la sclérose latérale amyotrophique (sla) |
EP3031820A1 (fr) | 2014-12-08 | 2016-06-15 | Life Science Inkubator | Particules viroides (VLP) comportant un peptide de ciblage |
EP3230441A4 (fr) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions et méthodes pour la production de scaav |
US20180030096A1 (en) | 2015-02-03 | 2018-02-01 | University Of Florida Research Foundation, Inc. | Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof |
US10648000B2 (en) | 2015-02-16 | 2020-05-12 | University Of Florida Research Foundation, Incorporated | rAAV vector compositions, methods for targeting vascular endothelial cells and use in treatment of type I diabetes |
US10081659B2 (en) | 2015-04-06 | 2018-09-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Adeno-associated vectors for enhanced transduction and reduced immunogenicity |
PT3298134T (pt) | 2015-05-16 | 2023-08-18 | Genzyme Corp | Edição génica de mutações intrónicas profundas |
CA2990193A1 (fr) | 2015-06-23 | 2016-12-29 | The Children's Hospital Of Philadelphia | Facteur ix modifie, et compositions, methodes et utilisations pour un transfert de genes dans des cellules, des organes et des tissus |
AU2016332821B2 (en) | 2015-09-28 | 2022-02-17 | The University Of North Carolina At Chapel Hill | Methods and compositions for antibody-evading virus vectors |
WO2017147477A1 (fr) * | 2016-02-26 | 2017-08-31 | University Of Florida Research Foundation, Inc. | Mutants d'héparine aav qui présentent une transduction significativement améliorée dans l'œil et le cerveau |
EP3448874A4 (fr) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
WO2017189964A2 (fr) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
RU2725286C2 (ru) | 2016-05-13 | 2020-06-30 | 4Д Молекьюлар Терапьютикс Инк. | Варианты капсидов аденоассоциированного вируса и способы их применения |
WO2017201258A1 (fr) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions et méthodes de traitement de la maladie de huntington |
EP3458588A4 (fr) | 2016-05-18 | 2020-01-15 | Voyager Therapeutics, Inc. | Polynucléotides modulateurs |
MX2019001938A (es) | 2016-08-15 | 2019-07-04 | Genzyme Corp | Metodos para detectar aav. |
EP3831281A1 (fr) | 2016-08-30 | 2021-06-09 | The Regents of The University of California | Procédés de ciblage et d'administration biomédicaux, et dispositifs et systèmes pour leur mise en uvre |
AU2017345470B2 (en) * | 2016-10-19 | 2023-08-03 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
CA3052829A1 (fr) * | 2017-02-15 | 2018-08-23 | The University Of North Carolina At Chapel Hill | Methodes et compositions pour le transfert de genes a travers le systeme vasculaire |
EP3597293B1 (fr) * | 2017-03-13 | 2023-07-26 | Mitsubishi Chemical Corporation | Zéolite portant un métal de transition et procédé de fabrication associé, et catalyseur de purification d'oxyde d'azote et son procédé d'utilisation |
US10550405B2 (en) | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
CA3054711A1 (fr) * | 2017-03-15 | 2018-09-20 | The University Of North Carolina At Chapel Hill | Vecteurs viraux adeno-associes polyploides et leurs procedes de fabrication et d'utilisation |
JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)治療組成物および方法 |
WO2018204803A1 (fr) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions et méthodes de traitement de la maladie de huntington |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
NZ763018A (en) | 2017-09-20 | 2023-02-24 | 4D Molecular Therapeutics Inc | Adeno-associated virus variant capsids and methods of use thereof |
AU2018352236A1 (en) | 2017-10-16 | 2020-04-23 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
WO2019079242A1 (fr) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Traitement de la sclérose latérale amyotrophique (sla) |
FI3717636T3 (fi) | 2017-11-27 | 2023-06-01 | 4D Molecular Therapeutics Inc | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä |
WO2019158619A1 (fr) * | 2018-02-15 | 2019-08-22 | Bjoerklund Tomas | Capsides virales modifiées |
EP3596203A4 (fr) * | 2018-05-07 | 2021-12-01 | The University Of North Carolina At Chapel Hill | Vecteurs de virus adéno-associés polyploïdes rationnels et leurs procédés de fabrication et d'utilisation |
US11821009B2 (en) | 2018-05-15 | 2023-11-21 | Cornell University | Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
WO2020041498A1 (fr) * | 2018-08-21 | 2020-02-27 | Massachusetts Eye And Ear Infirmary | Compositions et procédés pour moduler l'efficacité de transduction de virus adéno-associés |
WO2020174369A2 (fr) | 2019-02-25 | 2020-09-03 | Novartis Ag | Compositions et procédés pour traiter une dystrophie cristalline de bietti |
CN113677801A (zh) | 2019-02-25 | 2021-11-19 | 诺华股份有限公司 | 治疗bietti晶体营养不良的组合物和方法 |
US20210082541A1 (en) * | 2019-08-31 | 2021-03-18 | Wyatt Technology Corporation | Measuring attributes of a viral gene delivery vehicle sample via separation |
US11905523B2 (en) | 2019-10-17 | 2024-02-20 | Ginkgo Bioworks, Inc. | Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C |
WO2024006433A1 (fr) * | 2022-06-30 | 2024-01-04 | Carnegie Mellon University | Procédé de production de particules de type viral pour la délivrance de gènes |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69434447T2 (de) * | 1993-06-07 | 2006-05-18 | Vical, Inc., San Diego | Für die gentherapie verwendbare plasmide |
US6204059B1 (en) * | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US5741683A (en) * | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
JP2001500376A (ja) | 1996-09-06 | 2001-01-16 | カイロン コーポレイション | 組換えaavベクターを使用する治療分子の肝臓特異的送達のための方法および組成物 |
US6221646B1 (en) | 1997-07-31 | 2001-04-24 | Chiron Corporation | Materials and methods for simplified AAV production |
AU3755900A (en) | 1999-03-15 | 2000-10-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US6329181B1 (en) | 2000-08-07 | 2001-12-11 | Neurologix, Inc. | Helper functions for recombinant vector production |
AU2001292881A1 (en) | 2000-09-20 | 2002-04-02 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
AU2002248297A1 (en) * | 2001-01-05 | 2002-07-16 | Children's Hospital, Inc. | Aav2 vectors and methods |
US6692815B2 (en) * | 2001-06-15 | 2004-02-17 | Vinylex Corporation | Extruded plastic lumber and method of manufacture |
US6723551B2 (en) * | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
AU2003221733A1 (en) * | 2002-04-17 | 2003-11-03 | University Of Florida Research Foundation, Inc. | Improved raav vectors |
NZ561656A (en) | 2002-05-01 | 2009-03-31 | Univ Florida | Improved rAAV expression systems for genetic modification of specific capsid proteins |
WO2004099423A1 (fr) | 2003-05-01 | 2004-11-18 | University Of Florida Research Foundation, Inc. | Vecteurs raav modifies par vp2 et leurs utilisations |
WO2004020600A2 (fr) * | 2002-08-28 | 2004-03-11 | University Of Florida | Aav modifies |
-
2003
- 2003-05-01 NZ NZ561656A patent/NZ561656A/en unknown
- 2003-05-01 AT AT03786493T patent/ATE405295T1/de not_active IP Right Cessation
- 2003-05-01 SI SI200331424T patent/SI1496944T1/sl unknown
- 2003-05-01 US US10/513,059 patent/US8802080B2/en active Active
- 2003-05-01 NZ NZ536274A patent/NZ536274A/en unknown
- 2003-05-01 EP EP03786493A patent/EP1496944B1/fr not_active Expired - Lifetime
- 2003-05-01 CA CA002483624A patent/CA2483624A1/fr not_active Abandoned
- 2003-05-01 WO PCT/US2003/013583 patent/WO2004027019A2/fr not_active Application Discontinuation
- 2003-05-01 AU AU2003295312A patent/AU2003295312B2/en not_active Ceased
- 2003-05-01 DK DK03786493T patent/DK1496944T3/da active
- 2003-05-01 DE DE60323078T patent/DE60323078D1/de not_active Expired - Fee Related
-
2005
- 2005-05-24 HK HK05104362.7A patent/HK1071518A1/xx not_active IP Right Cessation
-
2014
- 2014-07-08 US US14/326,293 patent/US20150005369A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1071518A1 (en) | 2005-07-22 |
NZ561656A (en) | 2009-03-31 |
US8802080B2 (en) | 2014-08-12 |
DE60323078D1 (de) | 2008-10-02 |
WO2004027019A3 (fr) | 2004-08-05 |
AU2003295312A1 (en) | 2004-04-08 |
EP1496944A4 (fr) | 2006-03-22 |
NZ536274A (en) | 2008-04-30 |
EP1496944A2 (fr) | 2005-01-19 |
SI1496944T1 (sl) | 2009-02-28 |
AU2003295312B2 (en) | 2008-08-14 |
US20060088936A1 (en) | 2006-04-27 |
CA2483624A1 (fr) | 2004-04-01 |
WO2004027019A2 (fr) | 2004-04-01 |
ATE405295T1 (de) | 2008-09-15 |
EP1496944B1 (fr) | 2008-08-20 |
US20150005369A1 (en) | 2015-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1496944T3 (da) | Forbedrede rAAV-ekspressionssystemer til genetisk modificering af specifikke sapsid-proteiner | |
PH12020550094A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
DE60033293D1 (de) | Neue b7-4 moleküle und deren verwendungen | |
WO2005077333A3 (fr) | Administration sous forme de gel de vecteurs de virus associes aux adenovirus recombines | |
DE60035517D1 (de) | Gl50 moleküle, sowie verwendungen derselben | |
WO2003042362A3 (fr) | Pgc-1$g(b), un nouvel homologue du pgc-1 et leurs utilisations | |
WO2002063025A3 (fr) | Transfert ameliore de genes vers des muscles a l'aide de virions d'aav-1 et de aav-6, de recombinaison | |
DE60031418D1 (de) | 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen | |
ATE480620T1 (de) | Neue pgc-1-isoformen und deren verwendungen | |
ES2226597T1 (es) | Vectores recombinantes virales y no virales que contienen el gen humano de urokinasa del activador del plasminogeno y su utilizacion en el tratamiento de varios tipos de fibrosis hepatica, renal, pulmonar, pancreatica y cardiaca y cicatrices hipertroficas. | |
WO2002002148A3 (fr) | Compositions de therapie genique renfermant deux genes recombines, et methodes d'utilisation correspondantes | |
DK0781344T3 (da) | Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme | |
BR112022003206A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
WO2001083781A3 (fr) | 14094, un nouveau membre dans la famille de la trypsine humaine et son utilisation | |
DK1664315T3 (da) | AAV-vektorer til in vivo genterapi af rheumatoid arthritis | |
DE60237236D1 (de) | Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür | |
ATE445714T1 (de) | 15603, ein mitglied der humanen ionenkanal- familie | |
WO2002016568A3 (fr) | 46863, methyltransferase humaine, et utilisations | |
WO2003035840A3 (fr) | 69583 et 85924, nouveaux membres d'une famille de proteine kinase humaine et utilisations associees | |
DE60136832D1 (de) | Atcr-1, eine humane acyltransferase und verwendungen davon | |
WO2001068806A3 (fr) | 26934, nouvelle molecule de type cytidine deaminase et ses utilisations | |
AU2001288284A1 (en) | 14189, a human kinase and uses thereof | |
WO2002048330A3 (fr) | 21908 et 21911, membres de la famille de la guanylate kinase, et leurs utilisations | |
WO2001064908A3 (fr) | La 14790, nouvelle molecule de proteine kinase et ses utilisations | |
WO2003038040A3 (fr) | 32235, membre de la famille de l'aminotransferase humaine et ses utilisations |